We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Out of Specification for Tisagenlecleucel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04094311
Recruitment Status : Recruiting
First Posted : September 18, 2019
Last Update Posted : October 18, 2022
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated.

Condition or disease Intervention/treatment Phase
B-cell Acute Lymphoblastic Leukemia Diffuse Large B-cell Lymphoma Biological: CTL019 Phase 3

Detailed Description:

This is a single-arm, open-label, multicenter, interventional Phase IIIb study in pediatric/young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (pALL) and adult patients with r/r large B-cell lymphoma (LBCL) including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B cell lymphoma, and DLBCL arising from follicular lymphoma for Part 1 and and r/r ALL and r/r non-Hodgkin's lymphomas (NHL) for Part 2

Patients whose final manufactured tisagenlecleucel patient-specific batch does not meet the approved local commercial release specifications are eligible for inclusion. Each case will be individually assessed and approved by the Novartis manufacturing facility and the Novartis global medical team (including Patient Safety). Following a single infusion of CTL019, the patient will be followed for 3 months for Part 1, and 1 day for Part 2.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercial Release in Patients Who Are Consistent With the Label Indication
Actual Study Start Date : November 21, 2019
Estimated Primary Completion Date : April 14, 2023
Estimated Study Completion Date : April 14, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Group A: pALL
Pediatric/young adult patients with r/r pALL who meet the indication in the Health Authority-approved CTL019 package insert in the respective country/region whose final manufactured product is OOS for commercial release, but it is considered that the benefit-risk profile may remain favorable and the usual expected benefits of infusing such a product outweigh the potential risks for the patient.
 Biological: CTL019
A single intravenous (i.v.) infusion of CAR-positive viable T cells.
Other Name: Tisagenlecleucel
Experimental: Group B: r/r LBCL
Adult patients with r/r LBCL including DLBCL not otherwise specified, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, that is consistent with the Health Authority-approved indication in the package insert for CTL019 in the respective country/region whose final manufactured product is OOS for commercial release, but it is considered that the benefit-risk profile may remain favorable and the usual expected benefits of infusing such a product outweigh the potential risks for the patient.
 Biological: CTL019
A single intravenous (i.v.) infusion of CAR-positive viable T cells.
Other Name: Tisagenlecleucel
Experimental: Group C: r/r NHL
Adult patients with r/r NHL in consistent with the Health Authority approved indication in the package insert for CTL019 in Japan whose final manufactured product is OOS for commercial release, but it is considered that the benefit-risk profile may remain favorable and the usual expected benefits of infusing such a product outweigh the potential risks for the patient.
 Biological: CTL019
A single intravenous (i.v.) infusion of CAR-positive viable T cells.
Other Name: Tisagenlecleucel


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of participants with Adverse Events (AEs) [ Time Frame: From Screening up to 3 months for Part 1 and 1 day for Part 2 ]
    Percentage of participants with Serious AEs (SAEs) and non-SAEs


Secondary Outcome Measures :
  1. Part 1: Overall Remission Rate in Group A (pALL) [ Time Frame: Up to 3 months ]
    Overall Remission Rate is defined as the percentage of participants wiho achieve a complete remission (CR) and CR with incomplete blood count recovery (CRi) within 3 months following infusion of CTL019 as determined by the local investigator assessment for participants in group A (part 1).

  2. Part 1: Overall Response Rate in Group B (LBCL) [ Time Frame: Up to 3 months ]
    ORR is defined as the percentage of patients who achieve a domplete response and partial response within 3 months following infusion of CTL019 as determined by the local investigator assessment for participants in group B (part 1).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key inclusion criteria:

  • Signed informed consent/assent must be obtained for this study prior to participation in the study.
  • Patients for whom the final manufactured tisagenlecleucel product does not meet the commercial release specifications.
  • Not excluded from commercial manufacturing under the Health Authority-approved tisagenlecleucel prescribing information for their respective country/region.
  • OOS material has not been deemed to pose an undue safety risk to the patient.
  • Patient is suffering from a serious or life-threatening disease or condition.
  • Repeat leukapheresis is not clinically appropriate per the investigator assessment.

Key exclusion criteria:

For part 1, patients meeting any of the following criteria are not eligible for inclusion in this study:

  • Human immunodeficience virus (HIV) positive patients.
  • Patients with active replication of Hepatitis B virus (HBV) or Hepatitis C virus (HCV).
  • Patients with primary central nervous system (CNS) lymphoma.
  • History of hypersensitivity to any drugs or metabolites of similar chemical classes as tisagenlecleucel.
  • Uncontrolled active infection or inflammation.
  • Any medical condition identified by the investigator that may impact the assessment of the safety or efficacy outcomes in relation to study treatment.
  • Pregnant or nursing (lactating) women. For part 2, exclusion criteria are not set; however, administration should be performed in accordance with the latest versions of the package insert of CTL019.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04094311


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals +41613241111 Novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +81337978748

Locations
Layout table for location information
Canada, Ontario
Novartis Investigative Site Completed
Hamilton, Ontario, Canada, L8V 5C2
Novartis Investigative Site Withdrawn
Ottawa, Ontario, Canada, K1H 8L6
Novartis Investigative Site Completed
Toronto, Ontario, Canada, M5G 1X8
Novartis Investigative Site Completed
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Novartis Investigative Site Withdrawn
Montreal, Quebec, Canada, H1T 2M4
Canada
Novartis Investigative Site Withdrawn
Quebec, Canada, G1R 2J6
Japan
Novartis Investigative Site Recruiting
Nagoya, Aichi, Japan, 466 8560
Novartis Investigative Site Recruiting
Fukuoka city, Fukuoka, Japan, 812-8582
Novartis Investigative Site Recruiting
Gifu-city, Gifu, Japan, 501-1194
Novartis Investigative Site Recruiting
Hiroshima City, Hiroshima, Japan, 734-8551
Novartis Investigative Site Recruiting
Sapporo city, Hokkaido, Japan, 060 8648
Novartis Investigative Site Recruiting
Kobe-city, Hyogo, Japan, 650-0047
Novartis Investigative Site Recruiting
Nishinomiya, Hyogo, Japan, 663 8501
Novartis Investigative Site Recruiting
Tsukuba city, Ibaraki, Japan, 305-8576
Novartis Investigative Site Recruiting
Kanazawa-city, Ishikawa, Japan, 920-8641
Novartis Investigative Site Recruiting
Kita-gun, Kagawa, Japan, 761-0793
Novartis Investigative Site Recruiting
Yokohama-city, Kanagawa, Japan, 236-0004
Novartis Investigative Site Recruiting
Kyoto-city, Kyoto, Japan, 602-8566
Novartis Investigative Site Recruiting
Tsu-city, Mie, Japan, 514-8507
Novartis Investigative Site Recruiting
Sendai city, Miyagi, Japan, 980 8574
Novartis Investigative Site Recruiting
Matsumoto-city, Nagano, Japan, 390-8621
Novartis Investigative Site Recruiting
Nagasaki-city, Nagasaki, Japan, 852-8501
Novartis Investigative Site Recruiting
Kurashiki-city, Okayama, Japan, 710-8602
Novartis Investigative Site Recruiting
Okayama-city, Okayama, Japan, 700-8558
Novartis Investigative Site Recruiting
Osaka Sayama, Osaka, Japan, 589 8511
Novartis Investigative Site Recruiting
Osaka-city, Osaka, Japan, 541-8567
Novartis Investigative Site Recruiting
Osaka-city, Osaka, Japan, 543-8555
Novartis Investigative Site Recruiting
Suita city, Osaka, Japan, 565 0871
Novartis Investigative Site Recruiting
Hamamatsu-city, Shizuoka, Japan, 431-3192
Novartis Investigative Site Recruiting
Bunkyo ku, Tokyo, Japan, 113 8655
Novartis Investigative Site Recruiting
Bunkyo ku, Tokyo, Japan, 113-8431
Novartis Investigative Site Recruiting
Bunkyo ku, Tokyo, Japan, 113-8677
Novartis Investigative Site Recruiting
Bunkyo-ku, Tokyo, Japan, 113-8519
Novartis Investigative Site Recruiting
Chuo ku, Tokyo, Japan, 104 0045
Novartis Investigative Site Recruiting
Minato-ku, Tokyo, Japan, 105-8471
Novartis Investigative Site Recruiting
Setagaya-ku, Tokyo, Japan, 157-8535
Novartis Investigative Site Recruiting
Shinjuku-ku, Tokyo, Japan, 160 8582
Novartis Investigative Site Recruiting
Chiba, Japan, 260 8677
Novartis Investigative Site Recruiting
Kyoto, Japan, 606 8507
Novartis Investigative Site Recruiting
Niigata, Japan, 951 8520
Novartis Investigative Site Recruiting
Osaka, Japan, 545-8586
Novartis Investigative Site Recruiting
Saitama, Japan, 330 8777
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04094311    
Other Study ID Numbers: CCTL019B2302
First Posted: September 18, 2019    Key Record Dates
Last Update Posted: October 18, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
out of specification
tisagenlecleucel
acute lymphoblastic leukemia
large B-cell lymphoma
 relapsed/refractory
pediatric
young adult patients
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma
Neoplasms by Histologic Type
Neoplasms
 Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia
Lymphoma, Non-Hodgkin